Takeda Pharmaceutical (NYSE:TAK) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Takeda Pharmaceutical (NYSE:TAK) released its earnings results on Thursday. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08, Zacks reports. Takeda Pharmaceutical had a return on equity of 10.00% and a net margin of 6.49%. Takeda Pharmaceutical updated its FY 2024 guidance to 3.330-3.330 EPS.

Takeda Pharmaceutical Trading Up 3.3 %

TAK traded up $0.44 on Thursday, reaching $13.75. 1,789,029 shares of the company traded hands, compared to its average volume of 1,994,364. The company has a market cap of $43.73 billion, a P/E ratio of 23.70, a price-to-earnings-growth ratio of 0.24 and a beta of 0.51. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. Takeda Pharmaceutical has a one year low of $12.57 and a one year high of $15.08. The firm has a fifty day simple moving average of $13.30 and a two-hundred day simple moving average of $13.89.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.